Company Overview
Tyra Biosciences, Inc. operates as a clinical-stage biotechnology entity dedicated to developing precision medicines focused on fibroblast growth factor receptor (FGFR) biology within the United States. The company leverages its proprietary platform, known as SNÅP, which facilitates drug design through iterative molecular snapshots to predict genetic outcomes. This specialized focus places Tyra Biosciences, Inc. within the Healthcare sector, specifically under the Biotechnology industry, where companies typically rely on significant research and development capital to advance therapies through clinical trials. With a reported market capitalization of $2.00B and an employee count of 87, the firm represents a mid-cap entity with a relatively lean workforce compared to large pharmaceutical peers. The market cap of $2.00B indicates that the market values the company's pipeline assets at a scale that suggests significant potential for future commercialization, while the absence of reported annual revenue highlights the pre-commercial nature of its business model typical for clinical-stage development firms.
Financial Health
The financial statements for Tyra Biosciences, Inc. reflect the heavy investment phase characteristic of biotechnology, with reported revenue (TTM) listed as N/A, a net income (TTM) of $-119,947,000, and an EBITDA of $-132,216,000. The substantial negative net income relative to the N/A revenue figure reveals a cost structure dominated by research and development expenditures rather than cost of goods sold, as the company has not yet generated significant product sales to offset operational costs. Free cash flow stands at $-54,550,248, indicating that the company is burning cash to fund its operations and pipeline development, which limits immediate financial flexibility but is a common requirement for clinical-stage biotechs. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that signifies the company is not yet profitable and that any current revenue is entirely consumed by costs before reaching the bottom line. On the balance sheet, the company holds $256.00M in cash against $5.81M in debt, resulting in a debt-to-equity ratio of 2.24. Despite the elevated debt-to-equity ratio, the liquidity position appears robust given the massive cash reserve relative to the minimal debt load. The current ratio is an exceptionally high 14.67, suggesting an abundance of short-term assets compared to short-term liabilities, which provides a strong buffer against liquidity risks. Return on Equity is -39.8% and Return on Assets is -25.7%, metrics that mathematically reflect the company's losses and indicate that management is currently deploying capital to generate negative returns as they invest in future growth rather than current profitability.
Valuation Assessment
Valuation metrics for Tyra Biosciences, Inc. present a complex picture due to the lack of earnings, with the P/E Ratio (TTM) listed as N/A and the Forward P/E at -14.96. The negative forward P/E implies that analysts or data providers expect earnings to remain negative or for the company to continue losing money over the next twelve months. The price-to-book ratio is 7.70, indicating that the market values the company's equity at a significant premium over its book value, likely reflecting the high perceived value of its intellectual property and pipeline assets. Alternative valuation metrics include a Price to Sales ratio of N/A and an EV/EBITDA of -13.24, figures that suggest the stock is priced based on asset value and revenue potential rather than current profitability or cash generation. The stock has traded between a 52-week low of $6.42 and a 52-week high of $39.15; without a specific current price provided in the source data, the position relative to this range cannot be calculated, but the wide range demonstrates significant volatility. The beta of 1.06 indicates that the stock's price volatility is roughly in line with the broader market, meaning it does not exhibit extreme sensitivity to market movements compared to high-beta biotechnology stocks.
Growth & Income
Growth metrics for Tyra Biosciences, Inc. show Revenue Growth (YoY) as N/A and Earnings Growth (YoY) as N/A, reflecting the company's stage where historical comparative growth rates are not applicable due to a lack of established revenue history. Since the company does not generate positive earnings, it is not possible to compare earnings growth to revenue growth in the traditional sense, but the N/A figures confirm that the primary focus remains on pipeline advancement rather than scaling revenue. As a non-dividend payer, the company reports a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning it does not distribute any cash to shareholders. Consequently, the company reinvests all available cash flow, including its $256.00M cash balance, directly into research, development, and clinical trials to advance its FGFR biology platform. The overall growth and income profile is defined by a reliance on external capital or cash reserves to fund operations rather than organic revenue growth or shareholder returns, a standard characteristic of clinical-stage biotechnology companies seeking to prove the efficacy of their drug candidates before commercial launch.